Bio-Techne CEO to Address J.P. Morgan Healthcare Conference
Event summary
- Bio-Techne CEO Kim Kelderman will present at the 2026 J.P. Morgan Healthcare Conference.
- The presentation is scheduled for Tuesday, January 13, 2026, at 9:00 a.m. PST.
- A live webcast will be available on Bio-Techne's Investor Relations website.
- Bio-Techne reported $1.2 billion in net sales for fiscal 2025.
- The company employs approximately 3,100 people globally.
The big picture
Bio-Techne's participation in the J.P. Morgan Healthcare Conference underscores the company's commitment to investor relations and its position within the broader life sciences tools and diagnostics sector. The conference provides a platform for Bio-Techne to communicate its strategic direction to a large audience of institutional investors and analysts, influencing perceptions of the company's value and growth potential. This appearance comes after a year of $1.2 billion in revenue, highlighting the company's scale and importance in the market.
What we're watching
- Growth Trajectory
- The conference presentation will likely address Bio-Techne's plans to sustain its recent revenue growth, particularly given the competitive landscape in the life sciences tools market.
- Strategic Focus
- Investors will be watching for any signals regarding potential acquisitions or shifts in Bio-Techne’s product portfolio, given the company’s broad range of offerings.
- Market Sentiment
- The reception of Kelderman’s presentation and subsequent analyst commentary will be a key indicator of overall market sentiment towards Bio-Techne’s valuation and future prospects.
Related topics